ARVN - NASDAQ

Arvinas, Inc.

Arvinas, Inc.

ARVNยทNASDAQ

$7.70

-3.8%
HealthcareBiotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$496.81M
EPS-1.2800
P/E Ratio-6.02
Earnings Date07/30/2026
Arvinas, Inc.

Arvinas, Inc. Fair Value Envelope

ARVN ยท NASDAQ

Our analysis suggests that ARVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.7, this represents a potential HIDDEN relative to our calculated worth for Arvinas, Inc..

HIDDEN
Intrinsic Value
Current Price: $7.7

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.4B
+ Cash & Equivalents$142.9M
Firm Value-$1.3B
- Debt$8.5M
Equity Value-$1.3B
/ Shares Outstanding72,644,801B
DCF Value-$18
OVERVALUED BY 328%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$258.5M
-$244.0M
-$230.4M
-$217.5M
-$205.3M
-$193.9M
-$183.0M
-$172.8M
-$163.1M
-$154.0M
Maintenance CapEx
-$358.8K
-$338.7K
-$319.8K
-$301.9K
-$285.0K
-$269.1K
-$254.0K
-$239.8K
-$226.4K
-$213.7K
Owner Earnings
-$258.8M
-$244.4M
-$230.7M
-$217.8M
-$205.6M
-$194.1M
-$183.3M
-$173.0M
-$163.4M
-$154.2M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$239.7M
-$209.5M
-$183.1M
-$160.1M
-$139.9M
-$122.3M
-$106.9M
-$93.5M
-$81.7M
-$71.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ARVN research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.